Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is increasingly being used to treat patients with lymphoma. As another effective treatment for lymphoma, allo-HSCT is a new treatment strategy for the poor conventional treatment patients. Historically, high levels of treatment-related mortality restricted the use of standard myeloablative allogeneic stem-cell transplantation. Over the last decade, an increasing number of patients with lymphoma have undergone allogeneic stem-cell transplantation (allo-SCT) using re - duced-intensity protocols that are associated with lower toxicity and reduced transplantation-related mortality. A graft-versus-lymphoma (GvL) effect is present in most entities, as evidenced by the generally lower relapse rates after allo-SCT and the results of donor lymphocyte infusions, being conducive to clearing minimal residual diseases (MRD), and increasing the chance of cure. Although reduced-intensity conditioning has lowered transplant-related mortality and improved the survival of patients with lymphoma, relapse rates in patients with HL and aggressive B-cell lymphomas, as well as in patients with heavily pre-treated and refractory lymphoma, remain high, hence further improvement is undoubtedly needed. Therefore, large prospective studies to clarify the effectiveness of allo-SCT are necessary. We summarized how allo-SCT was used in recent year in the treatment of HL, indolent lymphoma, and aggressive lymphomas (including mantle cell lymphoma and mature T-cell lymphoma).